Why the study?
Does an SAT2-type FMD inactivated vaccine protect pigs against experimental challenge with a homologous virus strain?
Does an SAT2-type FMD inactivated vaccine protect pigs against experimental challenge with a homologous virus strain?
Vaccination with an SAT2-type FMD inactivated vaccine protects pigs against clinical disease and viral shedding following homologous challenge.
May inform SAT2 FMD vaccine development in pigs; leaves open field efficacy and cross-protection.
FMDV serotype SAT2 is most frequently associated with outbreaks in ruminants. However, the risk of it spreading from cattle to pigs cannot be excluded. To assess the efficacy of an SAT2-type FMD inactivated vaccine against homologous challenge in pigs, a suitable challenge strain adapted to pigs was produced. After two passages in two pigs each, a FMDV stock of SAT2 challenge strain was produced. This material was used to infect two groups of five pigs. The first group being vaccinated 28 days before challenge and the other one left as an unvaccinated control. Clinical signs were recorded, virus shedding was assessed on mouth swabs, and neutralising antibody titres were determined. At least 80% of the vaccinated pigs were protected against clinical disease. Furthermore, no virus shedding was observed in any of the vaccinated pigs. This study shows that experimentally inoculated pigs can become infected with a SAT2 serotype. Furthermore, vaccination offers protection against generalisation and viral excretion, confirming the potential of vaccination as an important tool in the control of FMD in pigs.
No takes yet. Share an insight, caveat, or question.
Mouton et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: